Biomarin hopes to have a European approval of its potential new drug for the treatment of severe hemophilia A before summer 2022, the company reports in a press release in connection with its third quarter results.
Biomarin Chair and Chief Executive Jean-Jacques Bienaimé also promises to present data from the company's ongoing phase III trial with Valoctocogene Roxaparvovec in the beginning of 2022.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.